Climb Bio, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Climb Bio and Mabworks announced Phase 1 data for CLYM116/MIL116, an anti-APRIL monoclonal antibody for IgA nephropathy. Key findings: ~70% reduction in Gd-IgA1 and ~60% reduction in IgA at 12 weeks (800 mg dose), ~33-day half-life (3.5× sibeprenlimab), ≥90% free APRIL suppression sustained through 12 weeks supporting Q12W dosing, no dose-limiting toxicities or serious adverse events. NAVIGATE-2 Phase 2 trial enrolling with initial data expected H1 2027; global Phase 3 anticipated to initiate in 2027.
Why this rating
Early-stage biotech; positive Phase 1 pharmacodynamic data with best-in-class profile and favorable safety significantly de-risks late-stage development pathway relative to $44.8M market cap. Phase 3 initiation in 2027 is material milestone.
Price action (we called it positive)
before filing · preread $10.19 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.